Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
$8.55
-5.6%
$12.56
$0.88
▼
$17.25
$550.62M1.36357,177 shs380,645 shs
Annexon, Inc. stock logo
ANNX
Annexon
$3.10
-9.2%
$3.94
$3.07
▼
$7.18
$590.40M1.433.06 million shs4.45 million shs
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
$3.79
-5.3%
$3.83
$2.90
▼
$7.75
$237.82M0.28199,544 shs88,478 shs
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$10.23
-4.6%
$12.86
$6.96
▼
$16.93
$576.77M2.92866,637 shs690,937 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
+3.66%-13.88%-14.85%-33.87%+520.55%
Annexon, Inc. stock logo
ANNX
Annexon
-3.13%-14.11%-10.97%-32.74%-16.01%
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
-2.44%-2.20%+26.58%-10.71%+4.71%
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
+2.49%-11.48%-18.17%-32.28%-0.74%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
$8.55
-5.6%
$12.56
$0.88
▼
$17.25
$550.62M1.36357,177 shs380,645 shs
Annexon, Inc. stock logo
ANNX
Annexon
$3.10
-9.2%
$3.94
$3.07
▼
$7.18
$590.40M1.433.06 million shs4.45 million shs
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
$3.79
-5.3%
$3.83
$2.90
▼
$7.75
$237.82M0.28199,544 shs88,478 shs
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$10.23
-4.6%
$12.86
$6.96
▼
$16.93
$576.77M2.92866,637 shs690,937 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
+3.66%-13.88%-14.85%-33.87%+520.55%
Annexon, Inc. stock logo
ANNX
Annexon
-3.13%-14.11%-10.97%-32.74%-16.01%
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
-2.44%-2.20%+26.58%-10.71%+4.71%
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
+2.49%-11.48%-18.17%-32.28%-0.74%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
2.86
Moderate Buy$29.50245.03% Upside
Annexon, Inc. stock logo
ANNX
Annexon
2.33
Hold$13.33330.80% Upside
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
2.82
Moderate Buy$10.44175.58% Upside
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
2.82
Moderate Buy$30.22195.43% Upside

Current Analyst Ratings Breakdown

Latest CAMP, ANNX, FDMT, and ANL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/23/2026
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
Initiated CoverageBuy ➝ Strong-Buy$10.00
10/22/2026
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Reiterated RatingBuy
10/22/2026
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Reiterated RatingBuy$36.00
10/16/2026
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
UpgradeSell (E+) ➝ Sell (D-)
10/15/2026
Annexon, Inc. stock logo
ANNX
Annexon
Reiterated RatingSell (D-)
10/15/2026
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Reiterated RatingSell (D-)
10/15/2026
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
Initiated CoverageNeutral ➝ Buy$8.00
10/12/2026
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
Reiterated RatingSell (E+)
10/6/2026
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Lower Price TargetBuy$26.00 ➝ $25.00
10/5/2026
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
UpgradeStrong-Buy
10/5/2026
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
Initiated CoverageOutperform$15.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
$5M110.12N/AN/A($0.21) per share-40.71
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/A$0.75 per shareN/A
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
$3.50M67.95N/AN/A$1.71 per share2.22
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$85.21M6.77N/AN/A$5.99 per share1.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
-$35.53MN/AN/AN/AN/AN/AN/AN/AN/A
Annexon, Inc. stock logo
ANNX
Annexon
-$206.69M-$1.04N/AN/AN/AN/A-106.82%-76.75%N/A
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
-$80.40M-$2.14N/AN/AN/A-2,276.33%-182.39%-74.87%N/A
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$140.11M-$2.70N/AN/AN/A-208.57%-47.06%-40.05%N/A

Latest CAMP, ANNX, FDMT, and ANL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$1.05-$1.08-$0.03-$1.08$4.13 million$4.15 million
11/9/2026Q3 2026
Annexon, Inc. stock logo
ANNX
Annexon
-$0.2798-$0.25+$0.0298-$0.25$3.50 millionN/A
11/5/2026Q3 2026
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
-$0.20-$0.37-$0.17-$0.37N/A$1.90 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
N/AN/AN/AN/AN/A
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/AN/A
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
N/AN/AN/AN/AN/A
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
0.04
9.55
N/A
Annexon, Inc. stock logo
ANNX
Annexon
0.35
5.79
5.79
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
N/A
6.42
6.42
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
0.06
6.15
6.15

Institutional Ownership

CompanyInstitutional Ownership
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
35.21%
Annexon, Inc. stock logo
ANNX
Annexon
N/A
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
N/A
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
99.27%

Insider Ownership

CompanyInsider Ownership
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
N/A
Annexon, Inc. stock logo
ANNX
Annexon
10.31%
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
21.69%
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
7.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
10964.40 millionN/ANot Optionable
Annexon, Inc. stock logo
ANNX
Annexon
92190.76 million171.10 millionOptionable
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
4862.75 million49.14 millionNo Data
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
19656.38 million51.93 millionOptionable

Recent News About These Companies

HC Wainwright Issues Pessimistic Estimate for FDMT Earnings
4DMT Announces New Employment Inducement Grants
4DMT to Participate in Upcoming Investor Conferences

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Adlai Nortye stock logo

Adlai Nortye NASDAQ:ANL

$8.55 -0.51 (-5.63%)
Closing price 04:00 PM Eastern
Extended Trading
$8.56 +0.00 (+0.06%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Annexon stock logo

Annexon NASDAQ:ANNX

$3.10 -0.32 (-9.24%)
Closing price 03:58 PM Eastern
Extended Trading
$3.43 +0.33 (+10.73%)
As of 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

CAMP4 Therapeutics stock logo

CAMP4 Therapeutics NASDAQ:CAMP

$3.79 -0.21 (-5.25%)
Closing price 04:00 PM Eastern
Extended Trading
$3.82 +0.02 (+0.66%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location. The company also offers telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things marketplace, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from remote and mobile assets. In addition, it offers professional services, including project management, engineering services, and installation services. The company sells its products and services to customers in the automotive, telecommunications, industrial equipment, transportation and logistics, government and municipalities, insurance, original equipment manufacturers, and leasing companies. It markets through direct sales organization, channel partner program, original equipment manufacturers, and independent sales representatives and distributors, as well as its websites and digital platform. The company was incorporated in 1981 and is headquartered in Irvine, California.

4D Molecular Therapeutics stock logo

4D Molecular Therapeutics NASDAQ:FDMT

$10.23 -0.49 (-4.57%)
Closing price 04:00 PM Eastern
Extended Trading
$10.22 -0.02 (-0.15%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.